News Sentiment

NYKD sentiment intelligence

Nykode Therapeutics AS news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 50 Balanced news tone 4 relevant articles
Exchange OSL Norway
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.86 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 4

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-7.0% over one week, -9.2% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

NYKD: Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -7.0% Price reacting lower
Trend fit Trend active -9.2% over four weeks
Fair value -51.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 0
Neutral 4
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 4
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 2
Finansavisen 1
Business Wire 1

Event Lens

What the news is about

Classified themes
Market update 4

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-4 of 4